1 / 49

Immunity to tumors

Immunity to tumors. Tumor antigens Immune system’s reaction to tumor antigens How tumors evade the immune system Immunologic approaches to treatment of cancer. Cancers arise from the uncontrolled proliferation and spread of clones of malignantly transformed cells .

cybill
Download Presentation

Immunity to tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Immunity to tumors • Tumor antigens • Immune system’s reaction to tumor antigens • How tumors evadethe immune system • Immunologic approaches to treatment of cancer

  2. Cancers arise from theuncontrolledproliferation and spreadofclonesofmalignantlytransformedcells. Cancer is a major causeofdisease and death. About 1 of 5 deaths in industrialisedcountries is from cancer.

  3. The immune surveillancehypothesis Frank MacfarlaneBurnet 1956: The immune system constantlychecksourcells, and detects and destroysthosethataremalignantlytransformed.

  4. Contra: Most tumors are not more common in immunodeficientindividuals. Exception: Virus-induced tumors.

  5. Four reasons immune surveillancemay not work so well:

  6. Tumors are «self», not «foreign». Theydon’t have PAMPs, like pathogens do. 2) Most tumor cellslack HLA class II and costimulatorymolecules.

  7. 3) Tumors that do not cause inflammationmayinduce DC- mediatedtolerance. 4) Naive T cellscirculate in blood, lymph and secondarylymphoid organs, and do not usuallyenter peripheraltissues.

  8. Signof immune reaction to tumor: Lymphocyticinflammation.

  9. Demonstrationof tumor immunity

  10. Tumor antigens: • Tumor-specific • Unique to individual tumors • Sharedamong tumors • Tumor-associated • Viral antigens

  11. Cloned CTL lines identify tumor antigens from melanoma.

  12. Some tumor antigens:

  13. Mutated forms of cellular genes not involved in tumorigenesis: Various mutated proteins in melanomas recognized by CTLs

  14. Products of oncogenes and tumor suppressor genes: Oncogene products: Ras mutations (∼10% of human carcinomas), p210 tyrosine kinase product of Bcr/Ablchromosomal rearrangements (CML). Tumor suppressor gene products: Mutated p53 (present in ∼50% of human tumors).

  15. Unmutated but overexpressed products of oncogenes: HER2/Neu(tyrosine kinase; breast and other carcinomas)

  16. Products of genes that are silent in most normal tissues: Cancer/testis antigens expressed in melanomas and many carcinomas; normally expressed mainly in the testis and placenta

  17. Normal proteins overexpressed in tumor cells: Tyrosinase, gp100, MART in melanomas (normally expressed in melanocytes)

  18. Oncofetalantigens: Silenced during development, de-repressedwithmalignanttransformation. Diagnostictools. Carcinoembryonicantigen (CD66) on many tumors, also expressed in liver and other tissues during inflammation. α-Fetoprotein(alsoelevated in some non-neoplasticdiseases).

  19. Glycolipids and glycoproteins: • Gangliosides • Mucins

  20. Tissue-specific differentiation antigens: Prostate-specific antigen in prostate carcinomasCD20 on B cell lymphomas

  21. Products ofoncogenicviruses: Papillomavirus E6 and E7 proteins (cervical carcinomas) HPV vaccination EBNA-1 protein ofEpstein-Barr Virus (EBV-associatedlymphomas, nasopharyngealcarcinoma)

  22. Immune responses to tumors • Innate immunity • NK cells, macrophages • Adaptive immunity • T lymphocytes, antibodies

  23. NK cells Kill manycells in vitro, especiallycellswithlowexpressionof MHC class I. ADCC In vivo importanceunclear. LAK cells

  24. Macrophages M1 Mφ: Can kill tumor cells M2 Mφ: Canpromote tumor growth

  25. The principalmechanismof adaptive tumor immunity is killing of tumor cells by CD8+CTLs.

  26. Inductionof CTL responses to tumors by dendriticcell cross-presentation.

  27. Antibodies Little evidence for in vivo killing of tumors by host antibodies.

  28. Evasionof immune responses by tumors. Tumor editing – tumors become less immunogenic over time.

  29. Intrinsicmechanismsofevasion • Loss of antigen expression • Lackofcostimulators or HLA class II • Inhibitoryfactors

  30. Mechanisms by which tumors escape immune defenses

  31. Extrinsicfactors • Macrophageswith M2 phenotype • Regulatory T cells • Myeloid-derivedsuppressorcells

  32. Immunotherapy for tumors: • More specific and fewer side effectsthancurrenttherapies. • Stimulationofactive host immune responses or • Passive immunotherapy

  33. Stimulationofactive host immune responses • Vaccinationwith tumor antigens • Useofcostimulators and cytokines • Blockinginhibitorypathways • Nonspecificstimulation

  34. Tumor vaccines Type of Vaccine Vaccine Preparation Killed tumor vaccine Killed tumor cells + adjuvants Tumor cell lysates + adjuvants Purified tumor antigens Dendritic cell-based Dendritic cells pulsed with vaccines tumor antigens Dendritic cells transfected with genes encoding tumor antigens

  35. Dendriticcell-based tumor vaccines

  36. Enhancement of tumor cellimmunogenicity by transfectionofcostimulator and cytokine genes

  37. Counteracting T-cellinhibition.

  38. N Eng J Med July 11 2013 Nivolumab: Anti PD1 receptor Ipilimumab: Anti CTLA-4 (PD1 and CTLA-4 dampen T cellactivity.)

  39. Non-specificstimulation by systemiccytokinetherapy (a limitedsuccess). IL-2 (Melanoma, renal & colon cancer) IFN-α (Melanoma, carcinoid tumor) TNF (Sarcoma, melanoma) GM-CSF (to promote bone marrow recovery)

  40. Passive immunotherapy • Adoptive cellular therapy • Anti-tumor antibodies

  41. Adoptive cellular therapy LAK cells

  42. Anti-tumor antibodies. Mouse Ig is immunogenic for humans. «Humanization» ofmouseIg.

  43. -monab -ximab -zumab -mumab

  44. Mabs used in cancer treatment in Norway: Alemtuzumab CD52 Chroniclymphaticleukemia Bevacizumab VEGF Several cancer forms Cetuximab, Panitumumab EGFR EGFR+ colorectal cancer

  45. Rituximab, CD20 Non-Hodgkinlymphoma, chroniclymphaticleukemia Ofatumumab CD20 Chroniclymphaticleukemia Trastuzumab Her2 Her2+ mamma cancer

  46. Pertuzumab Her2R Her2+ mamma cancer Ipilimumab CTLA-4 Malignantmelanoma

  47. Catumaksomab EpCAM + CD3 Malign ascites(ascites is abnormalaccumulationof fluid in theabdominal cavity).

  48. Promotionof tumor growthby the immune system: • Chronicinflammation • Hepatitis B • Mutationscaused by freeradicals • Growth factors • M2 macrophages (VEGF, TGF-β)

More Related